Dimensional Fund Advisors Portfolio holdings
Dimensional Fund Advisors (DFA), founded in 1981 by David Booth and Rex Sinquefield and headquartered in Austin, Texas, is an investment management firm renowned for its evidence-based, low-cost approach to investing, grounded in academic research from Nobel laureates like Eugene Fama and Kenneth French. Managing hundreds of billions in assets, DFA focuses on systematic, passive strategies that tilt toward factors like small-cap, value, and profitability stocks, primarily through mutual funds and institutional portfolios rather than retail brokerage services. The firm’s philosophy eschews market timing and stock picking, instead emphasizing diversification and efficient market exposure, often requiring investors to access its funds through approved financial advisors. With a global presence and a reputation for disciplined, data-driven investing, DFA has carved a unique niche in the industry, blending academic rigor with practical application.
Top Buys
| 1 |
NVIDIA
NVDA
|
$962M |
| 2 |
Cisco
CSCO
|
$202M |
| 3 |
Amazon
AMZN
|
$165M |
| 4 |
Johnson & Johnson
JNJ
|
$153M |
| 5 |
Pinduoduo
PDD
|
$131M |
Top Sells
| 1 |
Meta Platforms (Facebook)
META
|
$468M |
| 2 |
Merck
MRK
|
$306M |
| 3 |
ATVI
Activision Blizzard Inc.
ATVI
|
$305M |
| 4 |
TWNK
Hostess Brands, Inc. Class A Common Stock
TWNK
|
$299M |
| 5 |
TRTN
Triton International Limited
TRTN
|
$282M |
Sector Composition
| 1 | Technology | 18.21% |
| 2 | Financials | 17.12% |
| 3 | Industrials | 13% |
| 4 | Consumer Discretionary | 11.26% |
| 5 | Healthcare | 10.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
3326
Patriot National Bancorp
PNBK
$158M
| $65K | ﹤0.01% |
16,980
-44
| -0.3% | -$169 |
|
3327
FreightCar America
RAIL
$160M
| $64.9K | ﹤0.01% |
24,052
+12,759
| +113% | +$34.4K |
|
3328
Zevia
ZVIA
$203M
| $64.1K | ﹤0.01% |
31,890
-2,766
| -8% | -$5.56K |
|
3329
Nuvation Bio
NUVB
$1.01B
| $63.8K | ﹤0.01% |
42,238
| – | – |
|
3330
MEI Pharma
MEIP
$159M
| $63.5K | ﹤0.01% |
10,946
| – | – |
|
|
SRT
3331
DELISTED
Startek Inc.
SRT
| $63.5K | ﹤0.01% |
14,389
-25,805
| -64% | -$114K |
|
3332
PharmaCyte Biotech
PMCB
$6.39M
| $63.3K | ﹤0.01% |
29,307
| – | – |
|
3333
Cytosorbents Corp
CTSO
$59.6M
| $62.7K | ﹤0.01% |
56,570
-22,888
| -29% | -$25.4K |
|
3334
Vince Holding
VNCE
$19.4M
| $61K | ﹤0.01% |
17,630
-853
| -5% | -$2.95K |
|
3335
Prelude Therapeutics
PRLD
$64M
| $60.9K | ﹤0.01% |
14,305
+3,117
| +28% | +$13.3K |
|
3336
Crexendo
CXDO
$194M
| $59.4K | ﹤0.01% |
+12,239
| New | +$59.4K |
|
|
WHLM
3337
DELISTED
Wilhelmina International, Inc
WHLM
| $58.6K | ﹤0.01% |
14,457
| – | – |
|
3338
Sphere 3D
ANY
$17.3M
| $57.5K | ﹤0.01% |
+17,318
| New | +$57.5K |
|
3339
Good Times Restaurants
GTIM
$17.1M
| $56.7K | ﹤0.01% |
22,331
| – | – |
|
3340
Vaalco Energy
EGY
$411M
| $55.6K | ﹤0.01% |
12,383
-73,250
| -86% | -$329K |
|
3341
Ocular Therapeutix
OCUL
$2.21B
| $55.3K | ﹤0.01% |
12,389
| – | – |
|
3342
BRF SA
BRFS
$5.81B
| $55.1K | ﹤0.01% |
19,831
-17,989
| -48% | -$50K |
|
3343
Edesa Biotech
EDSA
$16.5M
| $52K | ﹤0.01% |
+11,333
| New | +$52K |
|
3344
Gain Therapeutics
GANX
$68.7M
| $51.9K | ﹤0.01% |
15,886
-933
| -6% | -$3.05K |
|
3345
Lantern Pharma
LTRN
$43.5M
| $50.6K | ﹤0.01% |
+11,828
| New | +$50.6K |
|
|
UBX
3346
DELISTED
Unity Biotechnology
UBX
| $49.2K | ﹤0.01% |
25,500
-14,219
| -36% | -$27.4K |
|
|
LUMO
3347
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
| $48.7K | ﹤0.01% |
15,564
| – | – |
|
3348
IZEA Worldwide
IZEA
$67M
| $48.5K | ﹤0.01% |
24,150
+10,106
| +72% | +$20.3K |
|
|
KLRS
3349
Kalaris Therapeutics, Inc. Common Stock
KLRS
$74.8M
| $48.4K | ﹤0.01% |
71,169
-42,765
| -38% | -$29.1K |
|
3350
DiaMedica Therapeutics
DMAC
$275M
| $48.2K | ﹤0.01% |
16,959
| – | – |
|